https://www.biopharmadive.com/news/biogen-aduhelm-alzheimers-drug-discontinue-rights-neurimmune/706132/
Biogen quits Aduhelm, handing back rights to original developer | BioPharma Dive
The decision to discontinue the controversial drug closes a tumultuous three-year saga that brought significant upheaval to the company.
biopharma divebiogenquitsaduhelmback
https://pharmaphorum.com/news/biogen-bites-back-at-critics-of-aduhelm-after-drugs-slow-start
Biogen bites back at critics of Aduhelm after drug's slow start | pharmaphorum
Biogen has reported $2m in sales for newly-launched Alzheimer's therapy Aduhelm that came in below its expectations, prompting the company to issue a rebuke to...
biogenbitesbackcriticsaduhelm
https://hebertsrx.com/patient-resources/article/1706719630792/biogen-is-dropping-controversial-alzheimers-drug-aduhelm
Biogen Is Dropping Controversial Alzheimer's Drug Aduhelm | Hebert Pharmacy (207) 868-2242 | Van...
Looking for a local pharmacy with a personal touch? Hebert Pharmacy offers traditional quality service with modern-day conveniences. Try us today!
biogendroppingcontroversialalzheimerdrug
https://www.kalw.org/2022-04-08/medicare-has-decided-to-sharply-limit-coverage-of-aduhelm-a-new-alzheimer-drug
Medicare has decided to sharply limit coverage of Aduhelm, a new Alzheimer drug | KALW
Apr 8, 2022 - Medicare officials announced on Thursday that the health insurance program for older Americans will sharply limit coverage of a costly and controversial new...
has decidedmedicaresharplylimitcoverage
https://www.foxbusiness.com/lifestyle/fda-approval-alzheimers-drug-aduhelm-rife-irregularities-house-report-says
FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says | Fox...
A report by two House committees found that the Food and Drug Administration's controversial approval of the Alzheimer's drug Aduhelm was "rife with...
fda approvalalzheimerdrugaduhelmrife
https://kffhealthnews.org/morning-breakout/acting-fda-chief-says-agency-may-have-mishandled-aduhelm-approval/
Acting FDA Chief Says Agency May Have Mishandled Aduhelm Approval - KFF Health News
Jul 15, 2021 - Acting Commissioner Janet Woodcock was emphatic in her defense of the drug, and the Food and Drug Administration's approval, but admitted possible poor...
kff health newsactingfdachiefsays